Cerenion has announced the launch of a €5 million share issue via the Springvest growth investment platform, inviting Finnish private investors and family offices to join the company’s next phase of international growth.
The share issue comes at a pivotal moment. Following MDR certification of C-Trend EEG Software in December 2025, Cerenion’s C-Trend® EEG Station has rapidly transitioned into its commercial rollout, securing distributor partnerships and initial orders across Europe.
After years of focused development, Cerenion’s successful evolution from a software company into a full EEG monitoring solution provider has unlocked significantly greater market potential. The company is now positioned to scale across Europe, targeting an estimated 3.6 million patients annually in a market valued at approximately €1.44 billion.
The share issue will fuel this expansion for international markets, strengthening Cerenion’s commercial footprint and accelerating adoption of its innovative EEG monitoring solutions.
Learn about the share issue (materials in Finnish): https://app.springvest.fi/rounds/361
Open share issue key information document (in Finnish) here.
Learn about Springvest, the organiser of the share issue: https://springvest.fi/en/about-springvest/
